Citations

Showing 10 of 108119 citations.

Colorectal Cancer Characteristics and Outcomes after Solid Organ Transplantation
Merchea, Amit , Shahjehan, Faisal , Croome, Kristopher P. , Cochuyt, Jordan J., Kasi, Pashtoon Murtaza , Li, Zhuo , Colibaseanu, Dorin T, Kasi, Pashtoon Murtaza , Croome, Kris P , Li, Zhuo , Colibaseanu, Dorin

Mayo Clinic

Journal of Oncology | February 28, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-8

10.1155/2019/5796108 | PMID 30941176 Get It

Background. Individuals after solid organ transplant may develop secondary malignancies. In our clinical practice, we noted an increasing number of individuals who developed colorectal cancers after solid organ transplantation. The primary aim of this study was to describe the characteristics and outcomes of the patients who developed colorectal cancer after solid organ transplant. Materials and Methods. Data was gathered and merged from several registries at Mayo Clinic to identify all patients who received a diagnosis of colon or rectal cancer and solid organ transplant. Continuous variables were summarized as mean (standard deviation) and median (range), while categorical variables were reported as frequency (percentage). Time to colorectal cancer after transplant and overall survival after cancer diagnosis were estimated using Kaplan-Meier method. Results. Initially, 115 colorectal cancer patients who also had a transplant were identified. The diagnosis of colorectal cancer was noted after solid organ transplant in 63 patients. The mean age at transplant was 57 years. Majority had received a kidney transplant (44.4%) followed by liver (36.5%). The median time to develop colorectal cancer was 59.3 months (range: 4.4-251.4 months). 15 (24.6%) were stage 4 at diagnosis and 13 (21.3%) had stage 3 colorectal cancer. Median overall survival was 30.8 months; 5-, 10- and 15-year survival were noted to be 42.5%, 17.9%, and 7.5%, respectively. None of the stage 4 patients were alive at 5 years; 5-year survival rate for stage 1, 2, and 3 patients was 77%, 50%, and 42%, respectively. Conclusions. Our study reports on one of the largest cohorts of patients of colorectal cancer that developed the cancer after solid organ transplant. Survival is extremely poor for advanced cases. However, long-term survivors are noted who developed the cancer at a relatively early stage. Colorectal screening recommendations may need to be revised for patients after solid organ transplant.
SLC35A2‐CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals
Sosicka, Paulina , Agadi, Satish , Almannai, Mohammed , Bacino, Carlos A. , Barone, Rita , Burton, Jennifer, Carlston, Colleen M. , Cohen, Julie S. , Coman, David , Dipple, Katrina M. , Dorrani, Naghmeh, Dobyns, William B. , Elias, Abdallah F. , Epstein, Leon G. , Gahl, William A. , Garozzo, Domenico , Hammer, Trine Bjørg , Haven, Jaclyn, Héron, Delphine, Herzog, Matthew , Hoganson, George, Hunter, Jesse M. , Jain, Mahim , Juusola, Jane, Lakhani, Shenela , Lee, Hane , Lewis, Katherine, Mak, Christopher Chun Yu , McKnight, Dianalee , Mendelsohn, Bryce A. , Mignot, Cyril , Mirzaa, Ghayda , Mitchell, Wendy G. , Muhle, Hiltrud, Nelson, Stanley F. , Olczak, Mariusz , Palmer, Christina G.S. , Partikian, Arthur , Pierson, Tyler Mark , Regan, Brigid M. , Sacoto, María J. Guillen , Scaglia, Fernando , Scheffer, Ingrid E. , Segal, Devorah , Singhal, Nilika S. , Striano, Pasquale, Sturiale, Luisa , Symonds, Joseph D. , Willis, Mary , Wolfe, Lynne A. , Yano, Shoji , Powis, Zöe , Suchy, Sharon F., Edmondson, Andrew C. , Grünewald, Stephanie , Longo, Nicola , Mak, Christopher C Y , Patterson, Marc C. , Ross, M Elizabeth , Scheffer, Ingrid E , Symonds, Joseph , Edmondson, Andrew C , Ng, Bobby G. , Botto, Lorenzo D. , Chung, Hon-Yin B , Juusola, Jane , Lee, Joy Li-Yueh , Lewis, Katherine, Lourenco, Charles , Quinonez, Shane C. , Tang, Sha , Vilain, Eric J. N. , Yang, Hui , Rosenfeld, Jill A. , Freeze, Hudson H.

Mayo Clinic

Human Mutation | February 28, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/humu.23731 | PMID 30817854 Get It

Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice
Humar, Atul , Razonable, Raymund R.

Mayo Clinic

Clinical Transplantation | February 28, 2019 | Volume: 33 | Issue: 9 | Pages: No page available

10.1111/ctr.13512 | PMID 30817026 Get It

AbstractCytomegalovirus (CMV) is one of the most common opportunistic infections that affect the outcome of solid organ transplantation. This updated guideline from the American Society of Transplantation Infectious Diseases Community of Practice provides evidence‐based and expert recommendations for screening, diagnosis, prevention, and treatment of CMV in solid organ transplant recipients. CMV serology to detect immunoglobulin G remains as the standard method for pretransplant screening of donors and transplant candidates. Antiviral prophylaxis and preemptive therapy are the mainstays of CMV prevention. The lack of a widely applicable viral load threshold for diagnosis and preemptive therapy is highlighted, as a result of variability of CMV nucleic acid testing, even in the contemporary era when calibrators are standardized. Valganciclovir and intravenous ganciclovir remain as drugs of choice for CMV management. Strategies for managing drug‐resistant CMV infection are presented. There is an increasing use of CMV‐specific cell‐mediated immune assays to stratify the risk of CMV infection after solid organ transplantation, but their role in optimizing CMV prevention and treatment efforts has yet to be demonstrated. Specific issues related to pediatric transplant recipients are discussed.
Two-Stage Revision of Total Hip Arthroplasty for Infection Is Associated with a High Rate of Dislocation
McAlister, Ian P. , Perry, Kevin I. , Mara, Kristin C. , Hanssen, Arlen D. , Berry, Daniel J. , Abdel, Matthew P. , Abdel, Matthew P , Mara, Kristin C , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | February 28, 2019 | Volume: 101 | Issue: 4 | Pages: 322-329

10.2106/jbjs.18.00124 | PMID 30801371 Get It

Background: Two-stage exchange is the most common form of treatment of chronic infection following total hip arthroplasty (THA). We examined the prevalence of, and risk factors associated with, hip instability following 2-stage exchange as well as the fate of reimplanted hip prostheses that dislocated. Methods: Data on 515 2-stage exchange THAs performed between 2000 and 2014 at a single institution were retrospectively reviewed. Risk factors for instability as well as postoperative reoperations and revisions were analyzed. The impact of dislocation on these outcomes was evaluated as well. The mean age at the time of reimplantation was 65 years, and the mean duration of follow-up was 5 years (range, 2 to 15 years). Results: Dislocation occurred in 52 hips following reimplantation (cumulative probability = 8.9% at 1 year). There was a higher risk of instability in women (hazard ratio [HR] = 1.8, p = 0.038) and in those who had a history of dislocation prior to the 2-stage revision (HR = 5.1, p < 0.001). Younger age, body mass index, number of previous operations, spacer type, surgical approach, use of a constrained liner, femoral head diameter, and persistent or recurrent infection were not found to be significant risk factors. Patients with an absent or ununited greater trochanter or abductor deficiency also had a higher rate of dislocation (HR = 30, p < 0.001), as did patients who underwent reimplantation with a megaprosthesis (HR = 6.0, p < 0.001). The risk of additional reoperations (HR = 121, p < 0.001) and revision surgery (HR = 13, p < 0.001) was significantly higher in patients who experienced a dislocation after the 2-stage exchange. Conclusions: Dislocation after 2-stage exchange THA continues to be a major concern, with the 1-year cumulative probability found to be 9% in the present study. Female sex, a history of dislocation, an absent or ununited greater trochanter or abductor deficiency, and reimplantation with a megaprosthesis were identified as risk factors for dislocation. There is a remarkable 121-fold increase in the rate of reoperations and a 13-fold increase in the rate of revisions in hips that dislocated after 2-stage exchange THA. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Abstract 446: Transcription Factor EB, Not mTOR is a Therapeutic Target for Rag GTPase Protein C S75Y-based Cardiomyopathy
Qiu, Qi , Ma, Xiao , Kim, Maengjo , Xu, Xiaolei

Mayo Clinic

Circulation Research | February 28, 2019 | Volume: 123 | Issue: Suppl_1 | Pages: No page available

10.1161/res.123.suppl_1.446 Get It

Rationale: We recently reported the association of S75Y, a point mutation in the Rag GTPase protein C ( RRAGC ) gene, with pediatric DCM. Because RRAGC directly binds and regulates mTOR and the S75Y mutation results in abnormally activated mTOR, these in vitro data prompts that the mTOR pathway could be harnessed for therapeutic benefits. Methods: We aimed to integrate in vitro neonatal rat ventricle cardiomyocytes (NRVCM) and in vivo zebrafish system to elucidate underling mechanism of RRAGC -S75Y-based cardiomyopathy, and to seek targeted therapeutic strategies. Results: Overexpression of RRAGC with S75Y mutation, but not RRAGC WT, significantly increased cell size of NRVCM, suggesting the establishment of a cellular model of RRAGC - S75Y-based cardiomyopathy. At the molecular level, overexpression of RRAGC S75Y mutant increased activity of mammalian target of rapamycin (mTOR) and decreased activity of transcription factor EB (tfeb), a direct downstream target of mTOR. Intriguingly, treatment with rapamycin, a mTOR inhibitor, did not affect cellular hypertrophy, whereas adenovirus-mediated overexpression of TFEB was able to rescue cellular hypertrophy induced by RRAGC S75Y mutation. Consistently, treatment with trehalose, an mTOR-independent tfeb activator, rescued cellular hypertrophy induced by RRAGC -S75Y. To confirm the in vitro results, we generated a knock-in (KI) zebrafish line harboring the S75Y corresponding point mutation in rragc via the TALEN (Transcription Activator-Like Effector Nucleases) technology. The cardiac function of rragc KI fish was determined by high frequency echocardiography, and the KI fish showed a significant decrease in fractional shortening compared with control littermates. Conclusion: Both cellular and in vivo models of RRAGC -S75Y-based cardiomyopathy have been generated. Studies in the cellular model suggested that tfeb, but not mTOR, is a therapeutic target for this particular type of cardiomyopathy. We will report our progress in validating this conclusion in our in vivo model, and will discuss potential mechanisms.
Abstract 386: Sex Differences in Vitamin D Alter Inflammation During Heart Disease
Mathews, Jessica, Douglass, Erika J. , Hill, Anneliese R., Hoyne, Jonathan , Bruno, Katelyn A. , Cooper, Leslie T. , Fairweather, DeLisa

Mayo Clinic

Circulation Research | February 28, 2019 | Volume: 123 | Issue: Suppl_1 | Pages: No page available

10.1161/res.123.suppl_1.386 Get It

An estimated 1 billion people worldwide have deficient or insufficient levels of vitamin D (VitD). Considerable evidence indicates that VitD deficiency is associated with an increased risk of autoimmune and cardiovascular disease (CVD), yet it remains unclear whether low VitD is simply a biomarker or has a true pathologic role. In this study we examined how sex differences in VitD influences various CVDs. We found that patients with CVD had significantly lower VitD than healthy controls (no ICD9/10 codes). In myocarditis patients low VitD correlated to poor ejection fraction (EF) in women with myocarditis (p=0.02), but high VitD correlated with low EF in men (p=0.04). In VDR knockout mice we found that VDR decreased myocarditis in females (p=2E-8) but increased inflammation in males (p=0.03) with an increase in total immune cells (p=0.02), CD3, CD4 and CD8 T cells (p=0.04), and the inflammasome in females. VDR altered Treg (p=0.04), mast cells (p=0.04) and cytokine profiles in males. Additionally, sera VitD levels were significantly higher in WT male mice with myocarditis compared to females. Our findings in VDR mice indicate that VitD/VDR reduces myocarditis in females, but increases disease in males. These data suggest that VitD sufficiency may increase inflammation in men, while VitD deficiency may make disease worse in women. These findings suggest that Vitamin D may have a role in the pathogenesis of inflammatory and cardiovascular disease.
Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning
Hippel, Christiana von , Rosenberg, Shoshana M. , Austin, S. Bryn , Sprunck‐Harrild, Kim , Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Borges, Virginia F. , Partridge, Ann H. , von Hippel, Christiana , Come, Steven , Partridge, Ann H , Borges, Virginia F

Mayo Clinic

Psycho-Oncology | February 28, 2019 | Volume: 28 | Issue: 5 | Pages: 1033-1040

10.1002/pon.5047 | PMID 30817075 Get It

AbstractObjectivesTo identify and characterize distinct trajectories of change in young women's sexual functioning over the first 5 years following breast cancer diagnosis.MethodsGroup‐based trajectory modeling was applied to the sexual functioning of 896 women diagnosed with stage I‐IV breast cancer at age 40 or younger. The Cancer Rehabilitation Evaluation System was used to evaluate women's symptoms of sexual dysfunction annually for 5 years.ResultsFive distinct trajectories of sexual functioning were identified: one asymptomatic, one minimally symptomatic, two moderately symptomatic, and one severely symptomatic trajectory. Twelve percent of women were asymptomatic throughout follow‐up. The plurality of women experienced stable mild symptoms (42%). Among those with moderate symptoms, some experienced improvement over time (22%) while others experienced deterioration (13%); 11% experienced stable severe symptoms that did not remit over time. Independent predictors of experiencing a symptomatic rather than asymptomatic trajectory (P < 0.05, two‐sided) included diagnosis with stage 2 versus 1 disease, ER positive disease treated with oophorectomy or ovarian suppression, being partnered, having anxiety, poorer body image, and greater musculoskeletal pain.ConclusionsWe identified distinct trajectories that describe the reported sexual symptoms in this cohort of young breast cancer survivors. The majority of women reported various degrees of sexual dysfunction that remained stable over the study period. There is, however, potential for improvement of moderate and severe symptoms of sexual dysfunction in early survivorship.
Gut microbiome meta-analysis reveals dysbiosis is independent of body mass index in predicting risk of obesity-associated CRC
White, James R. , Perrotta, Brittany G. , Jenkins, Gregory D. , Greathouse, K Leigh , Chia, Nicholas , Padgett, R. Noah , Chia, Nicholas , Chen, Jun

Mayo Clinic

BMJ Open Gastroenterology | February 28, 2019 | Volume: 6 | Issue: 1 | Pages: e000247

10.1136/bmjgast-2018-000247 | PMID 30899534 Get It

Objective Obesity is a risk factor for colorectal cancer (CRC), accounting for more than 14% of CRC incidence. Microbial dysbiosis and chronic inflammation are common characteristics in both obesity and CRC. Human and murine studies, together, demonstrate the significant impact of the microbiome in governing energy metabolism and CRC development; yet, little is understood about the contribution of the microbiome to development of obesity-associated CRC as compared to individuals who are not obese. Design In this study, we conducted a meta-analysis using five publicly available stool and tissue-based 16S rRNA and whole genome sequencing (WGS) data sets of CRC microbiome studies. High-resolution analysis was employed for 16S rRNA data, which allowed us to achieve species-level information to compare with WGS. Results Characterisation of the confounders between studies, 16S rRNA variable region and sequencing method did not reveal any significant effect on alpha diversity in CRC prediction. Both 16S rRNA and WGS were equally variable in their ability to predict CRC. Results from diversity analysis confirmed lower diversity in obese individuals without CRC; however, no universal differences were found in diversity between obese and non-obese individuals with CRC. When examining taxonomic differences, the probability of being classified as CRC did not change significantly in obese individuals for all taxa tested. However, random forest classification was able to distinguish CRC and non-CRC stool when body mass index was added to the model. Conclusion Overall, microbial dysbiosis was not a significant factor in explaining the higher risk of colon cancer among individuals with obesity.